HK1207863A1 - Pantothenate derivatives for the treatment of neurologic disorders - Google Patents

Pantothenate derivatives for the treatment of neurologic disorders

Info

Publication number
HK1207863A1
HK1207863A1 HK15108533.0A HK15108533A HK1207863A1 HK 1207863 A1 HK1207863 A1 HK 1207863A1 HK 15108533 A HK15108533 A HK 15108533A HK 1207863 A1 HK1207863 A1 HK 1207863A1
Authority
HK
Hong Kong
Prior art keywords
treatment
neurologic disorders
pantothenate
derivatives
pantothenate derivatives
Prior art date
Application number
HK15108533.0A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew Vaino
Marek Biestek
Martin Shkreli
Original Assignee
Retrophin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrophin Inc filed Critical Retrophin Inc
Publication of HK1207863A1 publication Critical patent/HK1207863A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
HK15108533.0A 2012-04-27 2015-09-01 Pantothenate derivatives for the treatment of neurologic disorders HK1207863A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261639602P 2012-04-27 2012-04-27
PCT/US2013/038458 WO2013163576A1 (en) 2012-04-27 2013-04-26 Pantothenate derivatives for the treatment of neurologic disorders

Publications (1)

Publication Number Publication Date
HK1207863A1 true HK1207863A1 (en) 2016-02-12

Family

ID=48428654

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108533.0A HK1207863A1 (en) 2012-04-27 2015-09-01 Pantothenate derivatives for the treatment of neurologic disorders

Country Status (25)

Country Link
US (3) US8673883B2 (xx)
EP (3) EP3112372B1 (xx)
JP (3) JP6254151B2 (xx)
KR (1) KR20150035550A (xx)
CN (2) CN106977544B (xx)
AU (3) AU2013251345B2 (xx)
BR (1) BR112014026817A2 (xx)
CA (1) CA2879314A1 (xx)
CY (2) CY1118198T1 (xx)
DK (2) DK2841438T3 (xx)
ES (2) ES2708813T3 (xx)
HK (1) HK1207863A1 (xx)
HR (2) HRP20161389T1 (xx)
HU (2) HUE029474T2 (xx)
IN (1) IN2014DN09584A (xx)
LT (2) LT3112372T (xx)
MX (1) MX360149B (xx)
PL (2) PL2841438T3 (xx)
PT (2) PT3112372T (xx)
RS (2) RS55319B1 (xx)
RU (2) RU2018112720A (xx)
SI (2) SI2841438T1 (xx)
SM (1) SMT201600395B (xx)
TR (1) TR201819263T4 (xx)
WO (1) WO2013163576A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3112372T (pt) * 2012-04-27 2019-01-17 Retrophin Inc Derivados do pantotenato para o tratamento de distúrbios neurológicos
US9896464B2 (en) 2013-10-25 2018-02-20 Retrophin, Inc. Pantothenate derivatives for the treatment of neurological disorders
EP2868662A1 (en) * 2013-11-04 2015-05-06 Acies Bio d.o.o. Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
AU2016366977A1 (en) 2015-12-08 2018-07-12 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders
MX2019009342A (es) * 2017-02-07 2019-10-02 Retrophin Inc Formulaciones de fosmetpantotenato solido.
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676976A (en) 1950-12-04 1954-04-27 Nat Res Dev Synthesis of pantothenic acid-4' phosphate
US2870188A (en) 1955-10-03 1959-01-20 Hoffmann La Roche Process for the manufacture of pantothenic acid 4'-phosphate and its salts
RU2002110463A (ru) * 1999-09-21 2004-02-27 Басф Акциенгезелльшафт (De) Способ и микроорганизмы для получения пантосоединений
AU2002326412A1 (en) 2001-07-20 2003-03-03 Oregon Health And Science University Novel human nucleic acids encoding a pantothenate kinase and methods of use
HUP0500383A2 (hu) * 2002-07-03 2005-08-29 Basf Ag Mikroorganizmusok és eljárások pantotenát fokozott termelésére
CA2618335C (en) 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Antiviral phosphoramidates of 4'-substituted pronucleotides
PT3112372T (pt) * 2012-04-27 2019-01-17 Retrophin Inc Derivados do pantotenato para o tratamento de distúrbios neurológicos

Also Published As

Publication number Publication date
AU2013251345A1 (en) 2014-11-27
SI2841438T1 (sl) 2016-12-30
CN106977544B (zh) 2019-06-07
AU2017239508B9 (en) 2019-06-13
ES2708813T3 (es) 2019-04-11
US20140135294A1 (en) 2014-05-15
EP3489248A1 (en) 2019-05-29
PT2841438T (pt) 2016-11-22
AU2013251345B2 (en) 2017-08-31
JP2019206553A (ja) 2019-12-05
SI3112372T1 (sl) 2019-04-30
AU2017239508A1 (en) 2017-10-26
CN104520307B (zh) 2016-12-21
PL2841438T3 (pl) 2017-08-31
DK2841438T3 (en) 2016-11-28
CN104520307A (zh) 2015-04-15
WO2013163576A1 (en) 2013-10-31
JP2017141257A (ja) 2017-08-17
JP2015515496A (ja) 2015-05-28
MX2014013048A (es) 2015-04-10
CN106977544A (zh) 2017-07-25
EP3112372A1 (en) 2017-01-04
AU2017239508B2 (en) 2019-05-23
AU2017239508C1 (en) 2019-11-07
BR112014026817A2 (pt) 2017-07-18
DK3112372T3 (en) 2019-02-18
EP2841438A1 (en) 2015-03-04
SMT201600395B (it) 2017-01-10
RS55319B1 (sr) 2017-03-31
HUE029474T2 (en) 2017-02-28
MX360149B (es) 2018-10-24
CY1121238T1 (el) 2020-05-29
RU2014147739A (ru) 2016-06-20
US9181286B2 (en) 2015-11-10
LT3112372T (lt) 2019-01-10
CA2879314A1 (en) 2013-10-31
US20130289001A1 (en) 2013-10-31
RS58336B1 (sr) 2019-03-29
KR20150035550A (ko) 2015-04-06
EP2841438B1 (en) 2016-08-10
JP6560284B2 (ja) 2019-08-14
TR201819263T4 (tr) 2019-01-21
PT3112372T (pt) 2019-01-17
HRP20190038T1 (hr) 2019-02-22
CY1118198T1 (el) 2017-06-28
EP3112372B1 (en) 2018-11-07
HRP20161389T1 (hr) 2016-12-02
US20160015727A1 (en) 2016-01-21
US8673883B2 (en) 2014-03-18
PL3112372T3 (pl) 2019-05-31
LT2841438T (lt) 2016-11-10
HUE042199T2 (hu) 2019-06-28
IN2014DN09584A (xx) 2015-07-17
JP6254151B2 (ja) 2017-12-27
US9629862B2 (en) 2017-04-25
RU2018112720A (ru) 2019-02-28
AU2019219733A1 (en) 2019-09-05
ES2600179T3 (es) 2017-02-07
RU2653497C2 (ru) 2018-05-10

Similar Documents

Publication Publication Date Title
HRP20181976T1 (hr) Postupci za liječenje poremećaja gubitka kose
IL225239A0 (en) Compounds for the treatment of acne and related diseases
HRP20190038T1 (hr) Derivati pantotenata namijenjeni liječenju neuroloških poremećaja
RS56595B1 (sr) Derivati estrogena za upotrebu u lečenju neuroloških poremećaja
HK1194665A1 (zh) 用於治療神經系統病症的組合物
HK1219224A1 (zh) 角結膜病症的治療劑
PT3351554T (pt) Disfunções relacionadas com o glúten
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
IL237912A0 (en) History of dihydro-6-azaphenylene for the treatment of the central nervous system, oncological diseases and similar disorders
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
EP2588146A4 (en) TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS BY L-METHYLFOLATE
IL236870B (en) History of hydroxystatin for the treatment of osteoarthritis
IL238363A0 (en) Methods for treating eye diseases
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
GB201207363D0 (en) Compounds for the treatment of metabolic disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210423